iRadimed Corporation (NASDAQ:IRMD - Get Free Report) CEO Roger Susi sold 5,000 shares of the business's stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $95.43, for a total value of $477,150.00. Following the completion of the transaction, the chief executive officer directly owned 2,297,500 shares in the company, valued at approximately $219,250,425. This trade represents a 0.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
iRadimed Stock Performance
iRadimed stock opened at $96.76 on Wednesday. The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of 58.64 and a beta of 1.06. iRadimed Corporation has a 52-week low of $47.48 and a 52-week high of $98.24. The stock's 50 day moving average price is $82.60 and its two-hundred day moving average price is $70.78.
iRadimed (NASDAQ:IRMD - Get Free Report) last released its earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.43 by $0.04. The company had revenue of $21.20 million for the quarter, compared to the consensus estimate of $20.50 million. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. On average, equities research analysts forecast that iRadimed Corporation will post 1.66 EPS for the current year.
iRadimed Announces Dividend
The business also recently disclosed a special dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Wednesday, December 17th will be issued a dividend of $0.50 per share. The ex-dividend date is Wednesday, December 17th. iRadimed's dividend payout ratio is currently 41.21%.
Analyst Ratings Changes
Several analysts have recently commented on the company. Zacks Research upgraded iRadimed to a "hold" rating in a research note on Tuesday, November 4th. Wall Street Zen lowered iRadimed from a "strong-buy" rating to a "buy" rating in a report on Sunday, October 26th. Lake Street Capital restated a "buy" rating and set a $100.00 price objective on shares of iRadimed in a report on Monday, November 3rd. Roth Capital set a $90.00 target price on iRadimed in a research report on Friday, October 31st. Finally, Weiss Ratings reissued a "buy (b-)" rating on shares of iRadimed in a research report on Thursday, December 4th. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, iRadimed presently has an average rating of "Moderate Buy" and a consensus price target of $87.33.
Check Out Our Latest Stock Analysis on iRadimed
Institutional Trading of iRadimed
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. CWM LLC raised its stake in shares of iRadimed by 62.2% in the third quarter. CWM LLC now owns 550 shares of the medical equipment provider's stock worth $39,000 after purchasing an additional 211 shares during the last quarter. Quarry LP bought a new stake in iRadimed during the third quarter worth $40,000. Tower Research Capital LLC TRC grew its holdings in iRadimed by 191.1% during the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider's stock worth $45,000 after buying an additional 495 shares in the last quarter. State of Alaska Department of Revenue purchased a new stake in iRadimed in the 3rd quarter valued at $47,000. Finally, Spire Wealth Management bought a new position in iRadimed during the 2nd quarter valued at $60,000. 92.34% of the stock is owned by institutional investors.
About iRadimed
(
Get Free Report)
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
